The pharmaceutical industry can reconfigure its considerable resources to develop innovative and meaningful business models that are based on services that improve access and adherence to prescription drugs for common chronic conditions. Such innovation beyond drug development is consistent with the core capabilities of large pharmaceutical companies and has the potential to achieve profit levels similar to those of its traditional models.
Subjects: Health Sciences
You do not have access to this book on JSTOR. Try logging in through your institution for access.
Log in to your personal account or through your institution.
Table of Contents
Export Selected Citations
Export to NoodleTools
Export to RefWorks
Export to EasyBib
Export a RIS file
(For EndNote, ProCite, Reference Manager, Zotero, Mendeley...)
Export a Text file